BridgeMD
Compares treatment options for Functional Neurological Disorder
Official title Clinical Evaluation of HRV Biofeedback in Functional Neurological Disorders Compared to Placebo
ClinicalTrials.gov ID: NCT06422819
What this study is testing
- What it's testing
- Evaluation of the clinical effects of the Heart Rate Variability biofeedback training with patients suffering from Functional neurological Disorders compared with placebo.
- You might receive a placebo (an inactive treatment) instead of the study drug. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 70
You may be able to join if
- Functional Neurological Disorders (FND) diagnosis must be medically established
- Participants must have a smartphone (android ou Iphone)
- Participants must be of the age of majority
- Participants must have signed an informed consent
- Sufficiently fluent in French to understand study documents and instructions
You likely can't join if
- Specially protected participants: juveniles, pregnant womens, nursing mothers, law's protection peoples
- Participants suffering from a severe psychiatric disease needing specialised attention
- History of severe neurosurgical pathology
- Alcohol dependence or drug use
- Participants suffering from or have suffered from a severe disease causing autonomic dysfunctions (heart failure, asthma, blood disease, renal...
- Participants taking medication which could be impact autonomic nervous system activity (anticholinergic, antiarrhythmics, clonidine, beta-blockers...
See the full eligibility criteria
- Functional Neurological Disorders (FND) diagnosis must be medically established
- Participants must have a smartphone (android ou Iphone)
- Participants must be of the age of majority
- Participants must have signed an informed consent
- Sufficiently fluent in French to understand study documents and instructions
- Consistency in performing repeated questionnaires
- Normal or corrected-to-normal visual acuity
- Specially protected participants: juveniles, pregnant womens, nursing mothers, law's protection peoples
- Participants suffering from a severe psychiatric disease needing specialised attention
- History of severe neurosurgical pathology
- Alcohol dependence or drug use
- Participants suffering from or have suffered from a severe disease causing autonomic dysfunctions (heart failure, asthma, blood disease, renal failure, peripheral neuropathy, vagotomy, thyroid disorder, alcoholism...
- Participants taking medication which could be impact autonomic nervous system activity (anticholinergic, antiarrhythmics, clonidine, beta-blockers, tricyclic anti-depressants, metronidazole)
- Participants placing under judicial or administrative supervisions
The study team makes the final eligibility decision.
Where it's taking place
- Montreal, Quebec, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Montreal, Quebec, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.